Serial #88174440
DEAD

Serial Number

88174440

Owner

TCR2 Therapeutics Inc.

Attorney

Aaron D. Hendelman

First Use Date

Jul 24, 2019

Filing Date

Oct 30, 2018

Add to watchlist:

No watchlists yet
View on USPTO

Serial #88174440 Trademark

Serial Number: 88174440 • Registration: 5892912

Serial #88174440 is a trademark filed by TCR2 Therapeutics Inc. on October 30, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

TCR2 Therapeutics Inc.

100 Binney Street, Suite 710
Cambridge, MA 02142

Entity Type: 03

Trademark Details

Filing Date

October 30, 2018

Registration Date

October 22, 2019

First Use Anywhere

July 24, 2019

First Use in Commerce

July 24, 2019

Published for Opposition

April 30, 2019

Cancellation Date

May 8, 2026

Goods & Services

Scientific research in the fields of pharmaceuticals, pharmaceutical research and development, laboratory testing, biotechnology, medicine, biologics, biotherapeutics, biosimilars, cancer treatment, oncology, and therapeutics, namely, polypeptide-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics; providing information on the subject of scientific research in the fields of pharmaceuticals, pharmaceutical research and development, laboratory testing, biotechnology, medicine, biologics, biotherapeutics, biosimilars, cancer treatment, oncology, and therapeutics, namely, polypeptide-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics

Biological and pharmaceutical preparations, namely, therapeutic cells, therapeutic proteins and therapeutic nucleic acids for human use for the treatment and prevention of cancer, inflammation and inflammatory diseases; pharmaceutical preparations for human use in the nature of biotherapeutics, medicines, and therapeutics, namely, pharmaceutical polypeptides, pharmaceutical antibodies, pharmaceutical nucleic acids, polypeptide-based therapeutics, cell-based therapeutics, RNA-based therapeutics, and DNA-based therapeutics for the treatment and prevention of cancer, inflammation and inflammatory diseases

Filing History

CANCELLED SEC. 8 (6-YR)
May 8, 2026 C8..
WITHDRAWAL OF ATTORNEY GRANTED
Aug 20, 2025 WOAG
TEAS WITHDRAWAL OF ATTORNEY RECEIVED
Aug 20, 2025 WOAR
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 22, 2024 REM1
REGISTERED-PRINCIPAL REGISTER
Oct 22, 2019 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sep 18, 2019 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Sep 17, 2019 CNPR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 13, 2019 EXRA
STATEMENT OF USE PROCESSING COMPLETE
Sep 12, 2019 SUPC
SOU EXTENSION 1 GRANTED
Sep 12, 2019 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 12, 2019 AITU
USE AMENDMENT FILED
Sep 9, 2019 IUAF
SOU EXTENSION 1 FILED
Sep 9, 2019 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 9, 2019 EEXT
TEAS STATEMENT OF USE RECEIVED
Sep 9, 2019 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 25, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 30, 2019 NPUB
PUBLISHED FOR OPPOSITION
Apr 30, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 10, 2019 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Mar 26, 2019 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 26, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 21, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 20, 2019 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 20, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 18, 2019 GNRN
NON-FINAL ACTION E-MAILED
Feb 18, 2019 GNRT
NON-FINAL ACTION WRITTEN
Feb 18, 2019 CNRT
ASSIGNED TO EXAMINER
Feb 6, 2019 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jan 31, 2019 AMPX
ASSIGNED TO LIE
Jan 29, 2019 ALIE
TEAS VOLUNTARY AMENDMENT RECEIVED
Jan 25, 2019 PARI
NOTICE OF DESIGN SEARCH CODE E-MAILED
Nov 15, 2018 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 14, 2018 NWOS
NEW APPLICATION ENTERED
Nov 2, 2018 NWAP